IP Library Granted Patent US 8,822,518
Granted Patent B2
US 8,822,518 · App. 14/103,893 · Granted Sep 2, 2014

Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction

Inventors: David John Cowan (Research Triangle Park, NC); Andrew Lamont Larkin (Research Triangle Park, NC); Cunyu Zhang (Research Triangle Park, NC); David Lee Musso (Research Triangle Park, NC); Gary Martin Green (Research Triangle Park, NC); Rodolfo Cadilla (Research Triangle Park, NC); Paul Kenneth Spearing (Research Triangle Park, NC); Michael Joseph Bishop (Research Triangle Park, NC); Jason Daniel Speake (Research Triangle Park, NC)
Assignee: GlaxoSmithKline LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,822,518
App. No.
14/103,893
Granted
Sep 2, 2014
Kind
B2
Abstract

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

Claims (10)

1. A method of treatment comprising administering a compound which is N-{[3,5-difluoro-3′-(1H-1,2,4-triazol-3-yl)-4-biphenylyl]methyl}-2,3-dihydro-1H-inden-2-amine or a salt thereof to a human suffering from drug addiction, substance addiction, or a combination thereof.

2. The method of claim 1 wherein said compound is a citrate, phosphate or mono- or di-hydrochloride salt of N-{[3,5-difluoro-3′-(1H-1,2,4-triazol-3-yl)-4-biphenylyl]methyl}-2,3-dihydro-1H-inden-2-amine.

3. The method of claim 2 wherein said compound is the citrate salt.

4. The method of claim 2 wherein said compound is the phosphate salt.

5. The method of claim 2 wherein said compound is the mono- or di-hydrochloride salt.

6. A method of treatment comprising administering a pharmaceutical composition comprising (i) a compound which is N-{[3,5-difluoro-3′-(1H-1,2,4-triazol-3-yl)-4-biphenylyl]methyl}-2,3-dihydro-1H-inden-2-amine or a salt thereof and (ii) at least one carrier or excipient to a human suffering from drug addiction, substance addiction, or a combination thereof.

7. The method of claim 6 wherein said compound is a citrate, phosphate or mono- or di-hydrochloride salt of N-{[3,5-difluoro-3′-(1H-1,2,4-triazol-3-yl)-4-biphenylyl]methyl}-2,3-dihydro-1H-inden-2-amine.

8. The method of claim 6 wherein said compound is the citrate salt.

9. The method of claim 6 wherein said compound is the phosphate salt.

10. The method of claim 6 wherein said compound is the mono- or di-hydrochloride salt.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2014
From: COWAN, DAVID JOHN; MUSSO, DAVID LEE; GREEN, GARY MARTIN; SPEARING, PAUL KENNETH; BISHOP, MICHAEL JOSEPH; SPEAKE, JASON DANIEL; LARKIN, ANDREW LAMONT; ZHANG, CUNYU; CADILLA, RODOLFO
To: GLAXOSMITHKLINE LLC
Reel/Frame 032180/0382 →
Continuity (3)
Continuation 12376580
Provisional Application 60821845 · Aug 9, 2006
Related Publication 20140100255A1 · Apr 10, 2014